US Edition
News from Verdict Hospital
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Verdict Hospital News
Eli LillyRepertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE:LLY) to develop tolerizing therapies for multiple autoimmune diseases. • Eli Lilly and Co stock is showing positive momentum. Where are LLY shares going? Repertoire Immune is a biotechnology company focused on the discovery and development of programmable T cell-targeted immune medicines. Under the terms of the agreement, Repertoire will receiv…See the Story
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion - Eli Lilly and Co (NYSE:LLY)
87% Center coverage: 8 sources
United States · United StatesOn Monday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of Anaphylm (dibutepinephrine) Sublingual Film for Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds). In January, the FDA identified deficiencies in Anaphylm's NDA that preclude discussion o…See the Story
What's Going On With Aquestive Therapeutics Stock Today? - Aquestive Therapeutics (NASDAQ:AQST)
100% Center coverage: 2 sources
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® ...
100% Left coverage: 1 sources
